1+ day, 17+ hour ago  (162+ words) The FDA has approved sacituzumab govitecan (Trodelvy) both by itself and in combination with pembrolizumab (Keytruda) as a first treatment for certain adults with advanced triple negative breast cancer, offering a new way to control the disease longer than standard…...

1+ week, 3+ day ago  (496+ words) The FDA has approved the combination of belzutifan (Welireg) and pembrolizumab (Keytruda) as adjuvant treatment for adults with clear cell renal cell carcinoma who are at intermediate-high or high risk of recurrence following surgery. Surgery is often the first and…...

1+ week, 3+ day ago  (474+ words) The FDA has approved capivasertib (Truqap) in combination with abiraterone and prednisone for adults with metastatic prostate cancer whose tumors are deficient in a tumor suppressor protein called PTEN. The approval marks the first targeted therapy specifically approved for this…...

1+ week, 4+ day ago  (413+ words) Ivonescimab plus chemotherapy helped patients with advanced squamous non-small cell lung cancer live longer than another immunotherapy-chemotherapy combination in the phase 3 HARMONi-6 trial. Learn what these results could mean for first-line lung cancer treatment and what questions patients should ask…...

2+ week, 3+ day ago  (272+ words) Medications known as GLP-1 receptor agonists have gained widespread attention for their ability to help people manage type 2 diabetes and obesity. Now, new research suggests these drugs may also be associated with a lower risk of breast cancer. The new…...

3+ week, 4+ day ago  (281+ words) A new targeted therapy called Beqalzi offers hope for patients whose mantle cell lymphoma has returned or stopped responding to treatment, with more than half of patients in clinical testing experiencing tumor shrinkage. The U. S. Food and Drug Administration (FDA) has…...